Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Boyko

Showing results (41-50 of 131) with videos related to

Pageof 14
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 23, 2014
Revised McDonald criteria for multiple sclerosis diagnostics in central Russia: sensitivity and specificityA N Belova, I V Shalenkov, D N Shakurova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 27, 2020
[The role of mitochondria in pathological mechanisms of innate immunity in multiple]A N Boyko, M V Melnikov, M S Kozin, et al.
Molekuliarnaia Biologiia|August 10, 2019
[Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis]E Yu Tsareva, O O Favorova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 13, 2021
[Treatment of multiple sclerosis with glatiramer acetate: a new look]A N Boyko, N F Smirnova, I A Shchukin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 1, 2022
[Expression analysis of miRNAs from the DLK1-DIO3 locus in CD4+ and CD14+ cells in patients with relapsing-remitting multiple sclerosis]N M Baulina, A R Kabaeva, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 22, 2017
[A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis]A N Boyko, E P Evdoshenko, O V Vorob'eva, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 13, 2021
[Ofatumumab - a new drug for the treatment of multiple sclerosis]A N Boyko, N F Smirnova, I A Shchukin, et al.
Human Genetics|September 27, 2015
A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approachesV V Bashinskaya, O G Kulakova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 15, 2020
[Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab]O V Boyko, I I Choroshilova, S V Petrov, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|November 19, 2025
[Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region]O G Kulakova, M S Kozin, I S Kiselev, et al.
Pageof 14

Showing results (41-50 of 131) with videos related to

Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 23, 2014
Revised McDonald criteria for multiple sclerosis diagnostics in central Russia: sensitivity and specificityA N Belova, I V Shalenkov, D N Shakurova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 27, 2020
[The role of mitochondria in pathological mechanisms of innate immunity in multiple]A N Boyko, M V Melnikov, M S Kozin, et al.
Molekuliarnaia Biologiia|August 10, 2019
[Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis]E Yu Tsareva, O O Favorova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 13, 2021
[Treatment of multiple sclerosis with glatiramer acetate: a new look]A N Boyko, N F Smirnova, I A Shchukin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 1, 2022
[Expression analysis of miRNAs from the DLK1-DIO3 locus in CD4+ and CD14+ cells in patients with relapsing-remitting multiple sclerosis]N M Baulina, A R Kabaeva, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 22, 2017
[A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis]A N Boyko, E P Evdoshenko, O V Vorob'eva, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 13, 2021
[Ofatumumab - a new drug for the treatment of multiple sclerosis]A N Boyko, N F Smirnova, I A Shchukin, et al.
Human Genetics|September 27, 2015
A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approachesV V Bashinskaya, O G Kulakova, A N Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 15, 2020
[Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab]O V Boyko, I I Choroshilova, S V Petrov, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|November 19, 2025
[Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region]O G Kulakova, M S Kozin, I S Kiselev, et al.
Pageof 14